We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-5.15%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$242M
AUM Growth
-$27.8M
Cap. Flow
-$11.1M
Cap. Flow %
-4.59%
Top 10 Hldgs %
37.51%
Holding
109
New
14
Increased
27
Reduced
32
Closed
36

Top Buys

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$7.67M
2
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$5.23M
3
PFE icon
Pfizer
PFE
+$4.48M
4
EVHC
Envision Healthcare Holdings Inc
EVHC
+$3.65M
5
GSK icon
GSK
GSK
+$3.41M

Top Sells

Rank Stock Value
1
AMSG
Amsurg Corp
AMSG
+$9.89M
2
AET
Aetna Inc
AET
+$5.01M
3
AGN
Allergan plc
AGN
+$4.99M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.37M
5
VWR
VWR Corporation
VWR
+$3.05M

Sector Composition

Rank Sector Weight
1 Healthcare 87.52%
2 Financials 2.14%
3 Energy 0%
4 Industrials 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNC icon
26
Centene
CNC
$30.7B
$3.6M 1.49%
127,352
-54,024
-30% -$1.59M
EVHC
27
DELISTED
Envision Healthcare Holdings Inc
EVHC
$3.54M 1.46%
+55,900
New +$3.65M
CAH icon
28
Cardinal Health
CAH
$53.9B
$3.53M 1.46%
49,100
+40,000
+440% +$2.89M
GSK icon
29
GSK
GSK
$104B
$3.33M 1.37%
+69,120
New +$3.41M
HSIC icon
30
Henry Schein
HSIC
$9.77B
$3.22M 1.33%
+54,060
New +$3.26M
PEN icon
31
Penumbra
PEN
$12.7B
$3.16M 1.31%
49,500
+42,300
+588% +$2.83M
CI icon
32
Cigna
CI
$73.7B
$3.09M 1.28%
23,150
-4,800
-17% -$628K
LLY icon
33
Eli Lilly
LLY
$1.02T
$2.8M 1.16%
+38,100
New +$2.84M
HCA icon
34
HCA Healthcare
HCA
$87.2B
$2.75M 1.13%
37,100
-20,300
-35% -$1.52M
BIIB icon
35
Biogen
BIIB
$30B
$2.7M 1.12%
9,532
-7,900
-45% -$2.34M
BBH icon
36
VanEck Biotech ETF
BBH
$400M
$2.65M 1.1%
24,650
+18,500
+301% +$2.01M
VTRS icon
37
Viatris
VTRS
$20.4B
$2.53M 1.04%
66,200
-24,774
-27% -$920K
AERI
38
DELISTED
Aerie Pharmaceuticals
AERI
$2.37M 0.98%
62,630
+20,600
+49% +$779K
AKRX
39
DELISTED
Akorn Inc
AKRX
$2.31M 0.96%
105,900
-8,200
-7% -$189K
ZBH icon
40
Zimmer Biomet
ZBH
$18.2B
$2.21M 0.91%
22,005
-11,175
-34% -$1.2M
INCY icon
41
Incyte
INCY
$24.2B
$2.02M 0.84%
20,200
+15,200
+304% +$1.48M
JAZZ icon
42
Jazz Pharmaceuticals
JAZZ
$15.9B
$1.79M 0.74%
+16,400
New +$1.83M
CTLT
43
DELISTED
CATALENT, INC.
CTLT
$1.59M 0.66%
59,008
+13,008
+28% +$322K
ACHC icon
44
Acadia Healthcare
ACHC
$2.76B
$1.48M 0.61%
+44,800
New +$1.74M
CRL icon
45
Charles River Laboratories
CRL
$11.2B
$1.41M 0.58%
18,488
-17,300
-48% -$1.31M
LH icon
46
Labcorp
LH
$25B
$1.4M 0.58%
12,702
-21,301
-63% -$2.37M
FOLD
47
DELISTED
Amicus Therapeutics
FOLD
$1.12M 0.46%
225,300
+182,400
+425% +$1.26M
STE icon
48
Steris
STE
$22.3B
$1.12M 0.46%
16,600
+7,100
+75% +$482K
EW icon
49
Edwards Lifesciences
EW
$49.6B
$993K 0.41%
+31,800
New +$1.03M
JNJ icon
50
Johnson & Johnson
JNJ
$618B
$968K 0.4%
8,400
-8,500
-50% -$982K
1
2
3 4 5

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, Endurant Capital Management held 109 positions worth $242M, down 10% from $270M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Endurant Capital Management withdrew a net $11.1M in Q4 2016, closing 36 positions and reducing 32 holdings. Its most notable exit was Amsurg Corp, an estimated $9.89M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 87% a quarter earlier, followed by Financials and Energy.

Against the trend, Endurant Capital Management opened a new position in Pfizer worth $4.52M.

  • Endurant Capital Management's largest Q4 2016 buy was Pfizer: 146,611 shares worth $4.52M.
  • Endurant Capital Management added most to Becton Dickinson in Q4 2016, an estimated $7.67M increase.
  • Endurant Capital Management's biggest Q4 2016 reduction was Aetna Inc, cutting an estimated $5.01M.
  • Endurant Capital Management fully exited Amsurg Corp in Q4 2016, selling an estimated $9.89M.
  • Endurant Capital Management's ten largest holdings make up 38% of its $242M portfolio in Q4 2016.
  • Endurant Capital Management opened 14 new positions and closed 36 in Q4 2016.
  • Endurant Capital Management's portfolio value fell 10% quarter-over-quarter to $242M.

Based on Endurant Capital Management's 13F filing for Q4 2016, filed 15 Feb 2017.